AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Capricor Therapeutics Shares Surge After FDA Meeting Announcement on Cell Therapy
ByAinvest
Friday, Aug 8, 2025 11:08 pm ET1min read
Capricor Therapeutics (CAPR) shares surged 9% following FDA meeting discussions on cell therapy Deramiocel. Analysts forecast a 125.88% upside from the current share price, with a current brokerage recommendation of "Outperform." The company has rescheduled its Q2 2025 financial release to August 11.
Capricor Therapeutics (NASDAQ: CAPR) shares have surged by 9% following a recent FDA meeting to discuss the regulatory path for the company's Biologics License Application (BLA) for its lead cell therapy candidate, Deramiocel. The meeting, scheduled for August 11, 2025, is a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the approval process for Deramiocel, which is aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD).The meeting has led to a significant increase in investor confidence, with analysts forecasting a 125.88% upside from the current share price. The company has also rescheduled the release of its second-quarter 2025 financial results to August 11, 2025, following the market close. This rescheduling is to accommodate the FDA meeting and provide a comprehensive corporate update.
Deramiocel, an allogeneic cardiac-derived cell therapy, has shown promise in preclinical and clinical studies, indicating its potential to preserve muscle function in muscular dystrophies such as DMD. The company's exosome-based therapeutics, developed using its proprietary StealthX™ platform, are also in preclinical development for various diseases.
The rescheduling of the financial results release demonstrates Capricor's commitment to transparency and allows investors to stay informed on both financial performance and strategic developments. However, the meeting with the FDA could imply potential regulatory challenges ahead for the approval of Deramiocel, indicating uncertainty in the product's market viability.
References:
[1] https://www.capricor.com/investors/news-events/press-releases/detail/322/capricor-therapeutics-announces-type-a-meeting-scheduled
[2] https://www.quiverquant.com/news/Capricor+Therapeutics+Schedules+FDA+Meeting+to+Discuss+Deramiocel+BLA+for+Duchenne+Muscular+Dystrophy
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet